da Silva, B S
Cupertino, R B
Rovaris, D L
Schuch, J B
Kappel, D B
Müller, D
Bandeira, C E
Victor, M M
Karam, R G
Mota, N R
Rohde, L A
Contini, V
Grevet, E H
Bau, C H D
Article History
Received: 22 November 2016
Revised: 10 February 2017
Accepted: 28 February 2017
First Online: 2 May 2017
Competing interests
: EHG was on the speaker’s bureau for Novartis and Shire for the last 3 years. He also received travel awards (air tickets and hotel accommodations) for participating in two psychiatric meetings from Shire and Novartis. LAR has received grant or research support from, served as a consultant to, and served on the speakers’ bureau of Eli Lilly and Co., Janssen, Medice, Novartis and Shire. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by LAR have received unrestricted educational and research support from the following pharmaceutical companies: Eli Lilly and Co., Janssen, Novartis and Shire. LAR has received travel grants from Shire to take part in the 2014 APA, 2015 WFADHD and 2016 AACAP congresses. He has received royalties from Artmed Editora and Oxford University Press. The remaining authors declare no conflict of interest.